Literature DB >> 1326785

Islet amyloid polypeptide-producing pancreatic islet cell tumor. A clinical and biochemical characterization.

M Stridsberg1, E Wilander, K Oberg, G Lundqvist, B Eriksson.   

Abstract

Islet amyloid peptide (IAPP) or amylin is a recently discovered polypeptide without settled physiology in man. We present a patient with an endocrine pancreatic tumor secreting huge amounts of IAPP-like immunoreactivity (20,000 mol/l) and a concomitant development of diabetes mellitus. The release of insulin and pancreatic polypeptide (PP) was totally absent after an oral glucose load and a mixed meal, respectively. Tumor secretion of IAPP-like immunoreactivity seemed to be influenced by cholinergic mechanisms and by nutrients. The observed effects on insulin and PP secretion by high circulating levels of IAPP-like immunoreactivity may be of beneficial value for further studies of the physiology of IAPP in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326785     DOI: 10.3109/00365529209000092

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

Review 1.  Amylin, amyloid and age-related disease.

Authors:  G J Cooper; C A Tse
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

2.  Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats.

Authors:  T A Lutz; J S Rand
Journal:  Can Vet J       Date:  1996-01       Impact factor: 1.008

3.  Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule.

Authors:  M Stridsberg; C Berne; S Sandler; E Wilander; K Oberg
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

4.  Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rats islets following dexamethasone treatment.

Authors:  H Mulder; B Ahrén; M Stridsberg; F Sundler
Journal:  Diabetologia       Date:  1995-04       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.